Foghorn Therapeutics (FHTX) Capital Expenditures Growth (1y) (2020 - 2025)
Foghorn Therapeutics (FHTX) Capital Expenditures Growth (1y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 143.40% |
| 10 | Foghorn Therapeutics | 345.61 Mn | 256.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -264.71% |
| Mar 31, 2025 | -72.28% |
| Dec 31, 2024 | -58.92% |
| Sep 30, 2024 | 1,165.52% |
| Jun 30, 2024 | 108.06% |
| Mar 31, 2024 | -66.11% |
| Dec 31, 2023 | 2,750.00% |
| Sep 30, 2023 | 92.87% |
| Jun 30, 2023 | -157.97% |
| Mar 31, 2023 | 20.65% |
| Dec 31, 2022 | 98.50% |
| Sep 30, 2022 | -276.96% |
| Jun 30, 2022 | -82.19% |
| Mar 31, 2022 | -74.24% |
| Dec 31, 2021 | 53.32% |
| Sep 30, 2021 | -95.76% |
| Jun 30, 2021 | 13.68% |
| Mar 31, 2021 | -34.81% |
| Dec 31, 2020 | -5,017.19% |